ClinicalTrials.gg
RecruitingNCT07424690ACE-AFUpdated Oct 8, 2026

Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation

An interventional study of Catheter Ablation for Atrial Fibrillation and Optimized Medical Therapy for Atrial Fibrillation in Atrial Fibrillation (AF), Atrial Fibrillation Ablation and Elderly, sponsored by Karolinska University Hospital. Recruiting at 2 sites in Sweden. Open to participants aged 78 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Karolinska University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
78 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.

Planned enrollment
53rd of 95
282 · median 361
Started
2026
with 2 others
No phase
44 of 135
12 open now
Primary completion
2031-12
later than 33 of 35 live
Registered
131st of 135
by date
Lead sponsor
5 of 135
Karolinska University Hospital

Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 53rd largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 44 with no phase, reaches primary completion later than 33 of the 35 other live ones, and was the 131st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 78 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Atrial Fibrillation with a site in Sweden, or all of them as a file.
02

Study summary

ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure.

The study compares two established treatment strategies:

  1. Catheter ablation (an invasive procedure aimed at reducing AF by electrically isolating triggers in the heart, primarily through pulmonary vein isolation), and
  2. Optimized medical therapy without AF ablation (medications for rate and/or rhythm control; AV node ablation with pacemaker may be used if clinically indicated according to routine care).

Participants are randomized 1:1 to one of these strategies. All participants will receive an implantable loop recorder (a small heart rhythm monitor placed under the skin) to continuously track heart rhythm and measure AF burden over time.

The study has two primary endpoints, tested with Holm-Bonferroni multiplicity control assessed over 24 months:

  1. a composite of major clinical events (all-cause mortality, stroke, major bleeding, cardiac arrest, or hospitalization due to heart failure), and
  2. patient-reported health-related quality of life (HRQoL), measured by the RAND-36 "General Health" domain.

ACE-AF will provide evidence to guide treatment decisions for very elderly patients with symptomatic AF and help identify which patients benefit most from an ablation-based strategy compared with optimized medical therapy.

Read the detailed description

Background and Rationale

Atrial fibrillation (AF) is highly prevalent in very elderly individuals and is associated with substantial morbidity, including stroke, heart failure (HF), recurrent hospitalisations, polypharmacy, frailty, and impaired health-related quality of life (HRQoL). Catheter ablation is an established rhythm-control therapy in AF, but patients aged ≥78 years have been under-represented in randomised trials, and evidence on comparative effectiveness and safety versus optimised medical therapy in this age group remains limited. ACE-AF is designed to address this knowledge gap using a pragmatic randomised strategy design and continuous rhythm monitoring in both arms.

Study Design

ACE-AF is an investigator-initiated, multicentre, parallel-group, open-label randomised controlled trial conducted at seven Swedish university hospitals and collaborating centres in Denmark, Australia and Greece. Participants aged ≥78 years with symptomatic paroxysmal or persistent AF are randomised 1:1 to an ablation-based strategy or to optimised medical therapy without AF ablation.

Randomisation is performed centrally using an electronic system with allocation concealment until assignment, stratified by sex and age group (78-83 vs >83 years).

Study Arms and Interventions

Arm A: Catheter ablation strategy Catheter ablation is performed according to contemporary clinical practice at experienced centres.

Pulmonary vein isolation (PVI) is prioritised as the primary ablation strategy. Energy source and tools are selected according to local practice and operator discretion, without restriction to a specific technology.

Periprocedural management (imaging, anticoagulation, anaesthesia strategy) follows local standards of care and the study protocol.

Arm B: Optimised medical therapy strategy (no AF ablation) Guideline-directed rate and/or rhythm control tailored to clinical need, including antiarrhythmic drugs and/or cardioversion when appropriate.

AV-node ablation with pacemaker implantation is permitted when clinically indicated, according to standard care.

Treatment optimisation and follow-up adhere to protocol-defined principles and local clinical routines.

Rhythm monitoring (both arms)

All participants receive an implantable loop recorder (ILR) to enable continuous rhythm monitoring, including quantification of AF burden and detection of clinically relevant arrhythmias over time (ILR programming per protocol).

Study Flow and Follow-up

Screening/Baseline (pre-randomisation/visit 1): informed consent; baseline clinical assessment including comorbidity profiling; baseline questionnaires and planned assessments per protocol.

ILR implantation for continuous monitoring will be performed according to protocol-defined timing/workflow between the first and second visit.

Randomisation (1:1): central, concealed allocation; stratified by sex and age group (78-83 vs >83 years).

Intervention phase (visit 2):

Ablation arm: catheter ablation performed as per protocol and site standards. Control arm: initiation/optimisation of medical therapy; AV-node ablation with pacing permitted if clinically indicated.

Follow-up visits: scheduled follow-up visits are performed at approximately 3, 12, 18 and 24 months after randomisation/intervention, with continuous ILR surveillance throughout follow-up. At follow-up, clinical events, adverse events, treatment changes, and patient-reported outcomes are collected according to protocol, and ILR rhythm summaries are reviewed.

Primary Outcomes (two primary endpoints, tested with Holm-Bonferroni multiplicity control.)

The endpoints are evaluated over 24 months after randomisation and controlled for multiplicity using the Holm-Bonferroni procedure:

Composite clinical endpoint: all-cause mortality, stroke, serious bleeding, cardiac arrest, or hospitalisation due to heart failure within 24 months after randomisation.

HRQoL endpoint: effect on HRQoL measured by the RAND-36 "General Health" domain.

Secondary Outcomes

Secondary outcomes include (as specified in the protocol):

AF burden and rhythm outcomes (ILR-derived): AF burden over time, recurrence patterns, and detection of clinically relevant rhythm events.

Healthcare utilisation: hospitalisations and AF/HF-related care contacts.

Patient-reported outcomes: symptom burden and HRQoL using validated instruments (including RAND-36 and additional AF-related questionnaires per protocol).

Safety outcomes: procedure-related and treatment-related complications and serious adverse events.

Treatment pathways: need for cardioversion, medication escalation, AV-node ablation with pacing, and crossover patterns (as applicable).

Exploratory Objectives and Planned Subgroup/Modifier Analyses

Exploratory analyses will examine whether treatment effects differ by baseline characteristics and geriatric domains, including:

Frailty (e.g., Frailty Index and/or Clinical Frailty Scale).

Cognitive status (protocol-defined assessment).

Inflammatory biomarkers and overall comorbidity burden.

Sex (sex-disaggregated reporting and interaction analyses).

AF type (paroxysmal vs persistent).

Imaging substudy (selected Swedish sites): a predefined subgroup (e.g., at Karolinska and Linköping) planned for brain and/or cardiac imaging with MRI and/or CT per protocol to explore mechanistic associations.

Saliva sampling (optional subgroup): in a predefined subgroup, saliva is collected for exploratory biomarker/genetic analyses relevant to ageing and treatment response (separate consent; optional participation).

If subgroup analyses are underpowered, results will be reported as exploratory.

Sample Size and Statistical Considerations

The planned sample size is 282 participants, providing adequate power to detect clinically meaningful differences over 24 months, accounting for crossover and loss to follow-up. Primary analyses are performed according to the intention-to-treat principle. Multiplicity across the two primary endpoints is addressed using a pre-specified Holm-Bonferroni approach.

Safety Oversight

Participant safety is overseen by an independent Data Monitoring Committee (DMC), comprising senior cardiology researchers independent of the study (Professor Eva Swahn, Professor Lars Lund, and Professor Johan Engdahl). Safety monitoring and adverse event reporting are conducted throughout the study according to the protocol.

Ethics, Regulatory, and Data Protection

The study has been approved by the Swedish Ethical Review Authority (Dnr 2025-02305-01; decision date 12 May 2025); amendment approved 19 May 2026 (Dnr 2026-02894-02). Data are pseudonymised and processed in compliance with GDPR, with data captured in an electronic CRF (REDCap).

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation Ablation
  • Elderly

Browse trials for

Keywords

  • atrial fibrillation
  • catheter ablation
  • rhtyhm control
  • rate control
  • implantable loop recorder
  • elderly
  • Health-related quality of life
  • Randomized controlled study
04

Who can participate

Ages eligible
78 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥78 years.
  2. -documented atrial fibrillation.
  3. AF type: paroxysmal, persistent, or longstanding persistent AF.
  4. Suitable candidate for catheter ablation according to ESC guidelines.
  5. Charlson's comorbidity index ≤7.

Exclusion criteria

Exclusion Criteria:

  1. Left atrial (LA) dimension >55 mm, based on echocardiography within the previous year.
  2. Acute coronary syndrome or coronary artery bypass surgery within the last 12 weeks.
  3. Severe valvular heart disease (per ESC definitions) or congenital heart disease.
  4. Prior surgical or catheter AF ablation procedure, or prior AV-node (atrioventricular nodal) ablation.
  5. to oral anticoagulation.
  6. AF due to a reversible cause.
  7. Medical condition likely to limit survival to \<12 months.
  8. Unable or unwilling to provide .
  9. History of non-compliance with medical therapy.
  10. \<18 or >37 kg/m².
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (estimated)

Study arms

  • Active comparator
    Catheter Ablation Strategy

    Participants randomized to this arm will undergo catheter ablation for atrial fibrillation, with pulmonary vein isolation (PVI) prioritized as the primary ablation strategy. Energy source and tools are selected according to local practice and operator discretion (no restriction to a specific technology). Participants will also receive an implantable loop recorder (ILR) for continuous rhythm monitoring throughout follow-up. Additional medical therapy may be used as clinically indicated according to guideline-based care.

    Procedure: Catheter Ablation for Atrial Fibrillation · Drug: Optimized Medical Therapy for Atrial Fibrillation · Device: Implantable Loop Recorder (ILR)

  • Active comparator
    Optimized Medical Therapy (Rate/Rhythm control) ± AV Node Ablation + Pacing

    Participants randomized to this arm will receive optimized guideline-directed medical therapy for atrial fibrillation without AF catheter ablation. Treatment may include rate control and/or rhythm control (including antiarrhythmic drugs and/or cardioversion when clinically appropriate). AV node ablation with pacemaker implantation is permitted when clinically indicated according to routine care. Participants will also receive an implantable loop recorder (ILR) for continuous rhythm monitoring throughout follow-up.

    Drug: Optimized Medical Therapy for Atrial Fibrillation · Procedure: AV Node Ablation With Pacemaker implantation

Interventions

  • ProcedureCatheter Ablation for Atrial Fibrillation

    Catheter ablation for symptomatic atrial fibrillation with pulmonary vein isolation (PVI) prioritized as the primary lesion set. Energy source and tools are selected according to local practice and operator discretion (no restriction to a specific technology), performed under routine standards of care at experienced centres.

    Also known as: catheter ablation, pulmonary vein isolation

  • DrugOptimized Medical Therapy for Atrial Fibrillation

    Guideline-directed rate and/or rhythm control tailored to the participant's clinical condition, including rate-control medications and/or antiarrhythmic drugs and cardioversion when clinically appropriate. AF ablation is not performed as part of this strategy.

    Also known as: Guideline-directed medical therapy, Rate control, Rhythm control

  • DeviceImplantable Loop Recorder (ILR)

    Subcutaneous implantable loop recorder used for continuous rhythm monitoring and quantification of atrial fibrillation burden throughout follow-up. Implanted in all participants according to protocol-defined workflow.

  • ProcedureAV Node Ablation With Pacemaker implantation

    AV node ablation with permanent pacing may be performed when clinically indicated according to routine care, as part of the optimized medical therapy strategy.

06

What researchers measure

Primary outcomes

  1. Composite clinical endpoint (all-cause mortality, stroke, serious bleeding, cardiac arrest, or heart failure hospitalization)

    First part of the co-primary outcome: Proportion of participants with ≥1 of the following events within 24 months after intervention (visit 2): all-cause death, stroke, serious bleeding, cardiac arrest, or hospitalization for heart failure. Events will be adjudicated per protocol.

    Time frame: 24 months after intervention (visit 2)

  2. Change in RAND-36 General Health score

    Second part of the co-primary outcome: Change from baseline in the RAND-36 "General Health" domain score at 24 months after the intervention (visit 2). Scores range 0-100; higher scores indicate better perceived health. Intention-to-treat. Because HRQoL is undefined after death, scores are not imputed for participants who die before the 24-month assessment; instead, deceased participants are assigned the worst rank (worst-rank / composite estimand, ICH E9(R1)) and the primary comparison uses a rank-based test. Missing data other than death are handled under a missing-at-random assumption with pre-specified sensitivity analyses.

    Time frame: Baseline to 24 months after intervention (visit 2)

Secondary outcomes

  1. Differences of atrial fibrillation and atrial tachycardia burden (ILR-derived) between groups

    Differences in percentage of time in atrial fibrillation and atrial tachycardia ("AF/AT burden") measured by continuous monitoring using an implantable loop recorder (ILR) between randomization groups.

    Time frame: From date of ILR implantation (intervention day, visit 2) up to 30 months after implantation.

  2. Hospitalizations (all-cause and cardiovascular)

    Number of hospital admissions, including cardiovascular/AF-related hospitalizations, collected from clinical records.

    Time frame: Up to 24 months after intervention

  3. Serious adverse events and treatment-related complications

    Serious adverse events (SAEs) and procedure-/treatment-related complications, including ablation-related and device-related complications, recorded and classified per protocol.

    Time frame: Up to 24 months after intervention

  4. Additional patient-reported outcomes (AF symptoms / disease-specific HRQoL)

    Symptom burden and AF-related quality of life assessed using validated questionnaires specified in the protocol (e.g., ASTA and/or AFEQT, as applicable).

    Time frame: Baseline and follow-up (3, 12, 18) through 24 months after intervention

  5. Changes in Left atrial reservoir strain (LASr)

    Left atrial function assessed as reservoir strain (LASr) by deformation imaging (speckle-tracking / deformation tracking, as per protocol). Reported as change from baseline to follow-up. Unit of measure: %

    Time frame: Up to 12 months after intervention (visit 2)

  6. Cognitive function measured by Montreal Cognitive Assessment (MoCA)

    MoCA total score assessed at follow-up visits. Reported as change from baseline

    Time frame: MoCA scores will be collected and assessed at baseline, 12, 18, and 24 months after intervention (visit 2).

  7. Frailty score assessed by e-Frailty index

    Frailty will be assessed using the e-Frailty index at baseline and follow-up. The outcome will be reported as a change in score from baseline to each follow-up time point.

    Time frame: Up to 24 months after intervention; visit 2 ( 12, 18, and 24 months)

  8. Discrimination of a prediction model for the ACE-AF primary composite outcome

    A multivariable prediction model (using baseline clinical variables and AI-derived features) will be developed to predict the time to first occurrence of the ACE-AF primary composite clinical outcome.

    Time frame: From baseline up to 24 months after intervention (visit 2).

  9. Predictors of differential treatment effect on AF/AT burden

    Baseline clinical variables (and AI-derived features, as available) will be evaluated as predictors of differential treatment effect on ILR-derived atrial fibrillation and atrial tachycardia (AF/AT) burden over follow-up.

    Time frame: From implantation (visit 2) up to 30 months after intervention

  10. Participants with at least one event in the composite neurological endpoint (dementia, stroke, intracranial hemorrhage)

    Composite neurological endpoint defined as the first occurrence of any of the following during follow-up: 1. Incident dementia 2. Stroke (ischemic or hemorrhagic) 3. Intracranial hemorrhage (including intracerebral hemorrhage and subarachnoid hemorrhage, per protocol definition) Results will be reported as number and percentage of participants with ≥1 composite event during follow-up.

    Time frame: Up to 24 months after intervention (visit 2).

  11. Total healthcare costs per participant

    Total direct healthcare costs per participant from intervention through follow-up, derived from healthcare utilization data (e.g., hospital inpatient/outpatient visits, procedures, emergency visits) and valued using standard regional/national tariffs per the health-economic analysis plan. Reported as mean/median cost per participant by group.

    Time frame: Up to 24 months after intervention (visit 2)

  12. All-cause mortality, stroke/TIA, serious bleeding, cardiac arrest, hospitalization due to heart failure analyzed separately

    Time frame: Up to 24 months after intervention

  13. Incident dementia

    Proportion of participants with a new diagnosis of dementia during follow-up, based on predefined diagnostic criteria and/or registry/medical record confirmation.

    Time frame: Up to 24 months after intervention (visit 2)

Other outcomes

  1. Discrimination of an inflammation proteomics-based prediction model for the ACE-AF primary composite outcome

    A predefined subgroup of patients included in the County of Stockholm and Östergotland will be analyzed using a targeted inflammation proteomics panel. A prespecified inflammation proteomics score will be computed from the panel. The score combined with baseline clinical covariates will be used to develop a prediction model for time to first occurrence of the ACE-AF primary composite outcome event.

    Time frame: Up to 24 months after intervention (visit 2).

  2. Correlation between change in Epicardial fat and the combined AF/AT burden

    Correlation between CT-derived Epicardial fat volume around LA the combined AF/AT burden measured by ILR through follow-up.

    Time frame: From implantation (visit 2) up to 24 months after the intervention

  3. Discrimination of a saliva proteomics-based prediction model for the primary composite outcome

    In a predefined subgroup providing separate consent, saliva samples will be analyzed using a proteomics platform. A prespecified salivary proteomics score will be used to develop a prediction model for the first occurrence of the study primary composite outcome event from baseline.

    Time frame: Baseline through 24 months after intervention

  4. Change from baseline in oral health-related quality of life (OHIP-14 total score)

    Patient-reported oral health-related quality of life measured using the Swedish version of the Oral Health Impact Profile (OHIP-14). The outcome will be reported as change from baseline in OHIP-14 total score.

    Time frame: Up to 12 months after baseline visit

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Hirata S, Okumura Y, Nagashima K, Watanabe R, Yokoyama K, Matsumoto N, Kato T, Fukaya H, Hayashi H, Nakahara S, Shimizu W, Iwasaki YK, Fujimoto Y, Mukai Y, Ejima K, Otsuka T, Suzuki S, Murakami M, Kimura M, Harada M, Koyama J, Yamane T, Tokuda M, Takami M, Shoda M, Harada T, Nakajima I, Hiroshima K, Tanimoto K, Kumagai K, Okada A, Kobayashi H, Watari Y, Hatsuno M, Hayashi T, Tachibana E, Iso K, Sonoda K, Aizawa Y, Fukuoka R, Chikata A, Inoue M, Sakagami S, Minamiguchi H, Makino N, Ichikawa M, Haruta H, Hiro T, Okubo K, Arai M, Arima K, Kihara H, Miyanaga S, Fukuda Y, Oiwa K, Koyama Y, Kurihara T, Akabane M, Ishikawa N, Kusano K, Miyamoto K, Tabuchi H, Shiozawa T, Miyamoto K, Mase H, Murotani K. Catheter Ablation Outcomes and Life Expectancy in Very Elderly Atrial Fibrillation Patients: The REHEALTH AF Study. JACC Clin Electrophysiol. 2026 Feb;12(2):307-321. doi: 10.1016/j.jacep.2025.10.007. Epub 2025 Nov 24. PubMed 41288543 ↗
  • Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kenneback G, Rubulis A, Malmborg H, Raatikainen P, Lonnerholm S, Hoglund N, Mortsell D. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA. 2019 Mar 19;321(11):1059-1068. doi: 10.1001/jama.2019.0335. PubMed 30874754 ↗
  • Akerstrom F, Hutter J, Charitakis E, Tabrizi F, Asaad F, Bastani H, Bourke T, Braunschweig F, Drca N, Englund A, Friberg L, Insulander P, Jonsson AH, Kenneback G, Paul-Nordin A, Sadigh B, Saluveer O, Saygi S, Schwieler J, Svennberg E, Tapanainen J, Turkmen Y, Jensen-Urstad M. Association between catheter ablation of atrial fibrillation and mortality or stroke. Heart. 2024 Jan 10;110(3):163-169. doi: 10.1136/heartjnl-2023-322883. PubMed 37657914 ↗
  • Orwelius L, Nilsson M, Nilsson E, Wenemark M, Walfridsson U, Lundstrom M, Taft C, Palaszewski B, Kristenson M. The Swedish RAND-36 Health Survey - reliability and responsiveness assessed in patient populations using Svensson's method for paired ordinal data. J Patient Rep Outcomes. 2017;2(1):4. doi: 10.1186/s41687-018-0030-0. Epub 2018 Feb 7. PubMed 29757320 ↗
  • Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. PubMed 1593914 ↗
  • Jung M, Yang PS, Kim D, Sung JH, Jang E, Yu HT, Kim TH, Uhm JS, Pak HN, Lee MH, Joung B. Multimorbidity in atrial fibrillation for clinical implications using the Charlson Comorbidity Index. Int J Cardiol. 2024 Mar 1;398:131605. doi: 10.1016/j.ijcard.2023.131605. Epub 2023 Nov 22. PubMed 38000669 ↗
  • Bahnson TD, Giczewska A, Mark DB, Russo AM, Monahan KH, Al-Khalidi HR, Silverstein AP, Poole JE, Lee KL, Packer DL; CABANA Investigators. Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. Circulation. 2022 Mar 15;145(11):796-804. doi: 10.1161/CIRCULATIONAHA.121.055297. Epub 2021 Dec 22. PubMed 34933570 ↗
  • Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693. PubMed 30874766 ↗
  • Santangeli P, Di Biase L, Mohanty P, Burkhardt JD, Horton R, Bai R, Mohanty S, Pump A, Gibson D, Couts L, Hongo R, Beheiry S, Natale A. Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. J Cardiovasc Electrophysiol. 2012 Jul;23(7):687-93. doi: 10.1111/j.1540-8167.2012.02293.x. Epub 2012 Apr 11. PubMed 22494628 ↗
  • Tabaja C, Younis A, Santangeli P, Madden R, Taigen T, Farwati M, Hayashi K, Braghieri L, Rickard J, Klein BM, Paul A, Dresing TJ, Martin DO, Bhargava M, Kanj M, Sroubek J, Nakagawa H, Saliba WI, Wazni OM, Hussein AA. Catheter ablation of atrial fibrillation in elderly and very elderly patients: safety, outcomes, and quality of life. J Interv Card Electrophysiol. 2024 Aug;67(5):1083-1092. doi: 10.1007/s10840-023-01659-w. Epub 2023 Oct 17. PubMed 37848806 ↗
  • Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen M, Chen SA, Dagres N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Purerfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2024 Sep;21(9):e31-e149. doi: 10.1016/j.hrthm.2024.03.017. Epub 2024 Apr 8. PubMed 38597857 ↗
  • Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010 Sep 7;56(11):827-37. doi: 10.1016/j.jacc.2010.05.028. PubMed 20813280 ↗
  • Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013 Nov;274(5):461-8. doi: 10.1111/joim.12114. Epub 2013 Aug 7. PubMed 23879838 ↗
  • Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available. PubMed 39210723 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the reported results, plus a data dictionary, will be shared with researchers whose proposal is approved by the ACE-AF steering committee, under a signed data-access agreement and controlled access, in compliance with GDPR, Swedish law and the study's ethics approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 6 months after publication of the primary results and ending 5 years thereafter.

Access criteria: Methodologically sound proposal approved by the ACE-AF steering committee; signed data-access/transfer agreement; controlled access consistent with GDPR, Swedish law and ethics approval.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2031, 62 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 62 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 20, 2026
StartActual
Oct 5, 2026was Sep 2026
Primary completionEst.
Dec 15, 2031
CompletionEst.
Sep 15, 2034
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added. Karolinska University Hospital is now Recruiting
Show site
  • Linköping University Hospital · Linköping, Sweden
Oct 8, 2026
Start date
Sep 15, 2026→Oct 5, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added. Karolinska University Hospital is now Recruiting
    Show site
    • Linköping University Hospital · Linköping, Sweden
    Start date Sep 15, 2026→Oct 5, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07424690
Collaborators
University Hospital, Linkoeping, Sahlgrenska University Hospital, University Hospital, Umeå, Dept of Cardiology, Örebro University Hospital, Sweden, Lund University Hospital, Onassis Cardiac Surgery Centre, Uppsala University Hospital, Royal Adelaide Hospital
Responsible party
Emmanouil Charitakis (MD, PhD, Karolinska University Hospital) — Principal investigator
First posted
Feb 20, 2026
Start date
Oct 5, 2026
Primary completion
Dec 15, 2031 (estimated)
Completion
Sep 15, 2034 (estimated)
Last update
Oct 8, 2026

Study contacts

Emmanouil Charitakis, MD, PhD
Contact
emmanouil.charitakis@regionstockholm.se
0046767877506
Nikola Drca, MD, PhD
Contact
emmanouil.charitakis@regionstockholm.se
+46705949838
Emmanouil Charitakis, MD, PhD
principal investigator · Karolinska University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion